Terry Lynch Joins BioNxt Solutions as Capital Markets Advisor

BioNxt Solutions Inc. announced that Terry Lynch has joined as a capital markets advisor. With extensive experience in resource and bioscience sectors, Lynch currently serves as the CEO of Power Nickel Inc. and co-founded Cardiol Therapeutics. He also established Save Canadian Mining to support Canada's junior mining sector.

Lynch expressed enthusiasm about BioNxt's developments, highlighting the positive toxicology and PK results for their sublingual Cladribine product for multiple sclerosis (MS). This product is expected to offer advantages for MS patients with difficulty swallowing, a common symptom. BioNxt aims to scale sublingual drug development for neurological disorders, with an anticipated European patent soon.

The company reported promising results from toxicity and PK studies, and plans a bioavailability study in early 2025. Additionally, BioNxt is progressing its sublingual drug delivery system for Myasthenia Gravis, an auto-immune disease.